These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38585861)

  • 1. CDHu40: a novel marker gene set of neuroendocrine prostate cancer (NEPC).
    Liu S; Nam HS; Zeng Z; Deng X; Pashaei E; Zang Y; Yang L; Li C; Huang J; Wendt MK; Lu X; Huang R; Wan J
    bioRxiv; 2024 Mar; ():. PubMed ID: 38585861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDHu40: a novel marker gene set of neuroendocrine prostate cancer.
    Liu S; Nam HS; Zeng Z; Deng X; Pashaei E; Zang Y; Yang L; Li C; Huang J; Wendt MK; Lu X; Huang R; Wan J
    Brief Bioinform; 2024 Sep; 25(6):. PubMed ID: 39318189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
    Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
    Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment-Emergent Neuroendocrine Prostate Cancer: A Clinicopathological and Immunohistochemical Analysis of 94 Cases.
    Zhang Q; Han Y; Zhang Y; Liu D; Ming J; Huang B; Qiu X
    Front Oncol; 2020; 10():571308. PubMed ID: 33598420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment-induced neuroendocrine prostate cancer and
    Wishahi M
    World J Clin Cases; 2024 May; 12(13):2143-2146. PubMed ID: 38808339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.
    Flores-Morales A; Bergmann TB; Lavallee C; Batth TS; Lin D; Lerdrup M; Friis S; Bartels A; Kristensen G; Krzyzanowska A; Xue H; Fazli L; Hansen KH; Røder MA; Brasso K; Moreira JM; Bjartell A; Wang Y; Olsen JV; Collins CC; Iglesias-Gato D
    Clin Cancer Res; 2019 Jan; 25(2):595-608. PubMed ID: 30274982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Models of Neuroendocrine Prostate Cancer.
    Cacciatore A; Albino D; Catapano CV; Carbone GM
    Curr Protoc; 2023 May; 3(5):e742. PubMed ID: 37166213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reciprocal deregulation of NKX3.1 and AURKA axis in castration-resistant prostate cancer and NEPC models.
    Sooreshjani MA; Kamra M; Zoubeidi A; Shah K
    J Biomed Sci; 2021 Oct; 28(1):68. PubMed ID: 34625072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L1CAM mediates neuroendocrine phenotype acquisition in prostate cancer cells.
    Hsieh CL; Do AD; Hsueh CY; Raboshakga MO; Thanh TN; Tai TT; Kung HJ; Sung SY
    Prostate; 2024 Dec; 84(16):1434-1447. PubMed ID: 39154281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
    Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
    Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer.
    Singh N; Ramnarine VR; Song JH; Pandey R; Padi SKR; Nouri M; Olive V; Kobelev M; Okumura K; McCarthy D; Hanna MM; Mukherjee P; Sun B; Lee BR; Parker JB; Chakravarti D; Warfel NA; Zhou M; Bearss JJ; Gibb EA; Alshalalfa M; Karnes RJ; Small EJ; Aggarwal R; Feng F; Wang Y; Buttyan R; Zoubeidi A; Rubin M; Gleave M; Slack FJ; Davicioni E; Beltran H; Collins C; Kraft AS
    Nat Commun; 2021 Dec; 12(1):7349. PubMed ID: 34934057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular model for neuroendocrine prostate cancer progression.
    Chen R; Dong X; Gleave M
    BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated analysis of single-cell and bulk transcriptomics develops a robust neuroendocrine cell-intrinsic signature to predict prostate cancer progression.
    Zhang T; Zhao F; Lin Y; Liu M; Zhou H; Cui F; Jin Y; Chen L; Sheng X
    Theranostics; 2024; 14(3):1065-1080. PubMed ID: 38250042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZBTB7A as a novel vulnerability in neuroendocrine prostate cancer.
    Bae SY; Bergom HE; Day A; Greene JT; Sychev ZE; Larson G; Corey E; Plymate SR; Freedman TS; Hwang JH; Drake JM
    Front Endocrinol (Lausanne); 2023; 14():1093332. PubMed ID: 37065756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression.
    Bakht MK; Derecichei I; Li Y; Ferraiuolo RM; Dunning M; Oh SW; Hussein A; Youn H; Stringer KF; Jeong CW; Cheon GJ; Kwak C; Kang KW; Lamb AD; Wang Y; Dong X; Porter LA
    Endocr Relat Cancer; 2018 Nov; 26(2):131-146. PubMed ID: 30400059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC.
    Lee CF; Chen YA; Hernandez E; Pong RC; Ma S; Hofstad M; Kapur P; Zhau H; Chung LW; Lai CH; Lin H; Lee MS; Raj GV; Hsieh JT
    Clin Transl Med; 2022 Feb; 12(2):e695. PubMed ID: 35184376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAQR6 Upregulation Is Associated with AR Signaling and Unfavorite Prognosis in Prostate Cancers.
    Yang M; Li JC; Tao C; Wu S; Liu B; Shu Q; Li B; Zhu R
    Biomolecules; 2021 Sep; 11(9):. PubMed ID: 34572596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting SOX4/PCK2 signaling suppresses neuroendocrine trans-differentiation of castration-resistant prostate cancer.
    Jing N; Tao Z; Du X; Wen Z; Gao WQ; Dong B; Fang YX
    Biol Direct; 2024 Jul; 19(1):56. PubMed ID: 39014441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-serum prostate-specific antigen level predicts poor outcomes in patients with primary neuroendocrine prostate cancer.
    Wang J; Xu W; Mierxiati A; Huang Y; Wei Y; Lin G; Dai B; Freedland SJ; Qin X; Zhu Y; Ye DW
    Prostate; 2019 Sep; 79(13):1563-1571. PubMed ID: 31376193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Master Neural Transcription Factor BRN2 Is an Androgen Receptor-Suppressed Driver of Neuroendocrine Differentiation in Prostate Cancer.
    Bishop JL; Thaper D; Vahid S; Davies A; Ketola K; Kuruma H; Jama R; Nip KM; Angeles A; Johnson F; Wyatt AW; Fazli L; Gleave ME; Lin D; Rubin MA; Collins CC; Wang Y; Beltran H; Zoubeidi A
    Cancer Discov; 2017 Jan; 7(1):54-71. PubMed ID: 27784708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.